NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib
- 492 Downloads
A recent study reported that treatment-free remission (TFR) of chronic myeloid leukemia (CML) after dasatinib (Das) treatment was significantly associated with natural killer (NK) cell proliferation in the peripheral blood. However, biomarkers to predict lymphocytosis or successful TFR are not well characterized. In order to clarify individual differences in NK cell responses among patients treated with Das, we retrospectively analyzed the association between polymorphisms in the natural killer group 2D receptor [NKG2D; also known as killer cell lectin like receptor K1 (KLRK1)] gene and clinical outcomes in 31 patients treated with Das as first-line treatment for CML. Patients with the NKG2D HNK1/HNK1 (high-cytotoxic activity-related allele on NKG2D hb-1) haplotype achieved MR4.5 more quickly than those with other haplotypes [hazard ratio (HR) 4.39; 95% confidence interval (CI) 2.75–118.6; P = 0.004]. In addition, NK cells with the NKG2D HNK1 allele exhibited enhanced phosphorylation of vav guanine nucleotide exchange factor 1 (VAV1) at Tyr174. These data suggest that NKG2D gene polymorphisms may represent candidate biomarkers for the prediction of TFR following Das treatment.
KeywordsChronic myeloid leukemia Natural killer cell Natural killer group 2D receptor Vav guanine nucleotide exchange factor 1 Single nucleotide polymorphism
The results of this study were presented in part at the 78th Japanese Society of Hematology Annual Meeting in Yokohama, Kanagawa, Japan, October 13–15, 2016 (Abstract Number OS-2-89), and at the 58th ASH Annual Meeting and Exposition in San Diego, CA, December 3–6, 2016 (Abstract Number 3091). The authors thank Inter-Biotech for help with the English language editing of this paper.
MO, EM, YN, HM, and KA designed the research study. MO, DO, HM, SM, KO, YS, YO, HK, and KA provided patients for the study. RH, MO, EM, EK, and YN were involved in the collection and analysis of the data. RH, MO, YN, and KA wrote the paper. All authors were involved in revising the manuscript and approved the final version.
Compliance with ethical standards
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of interest
The authors declare that they have no conflict of interest. A summary of relevant information will be published with the manuscript.
- 9.Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35.CrossRefPubMedGoogle Scholar
- 12.Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528–35.CrossRefPubMedGoogle Scholar
- 15.Espinoza JL, Takami A, Onizuka M, Sao H, Akiyama H, Miyamura K, et al. NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies. Haematologica. 2009;94(10):1427–34.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, et al. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am J Hematol. 2015;90(9):819–24.CrossRefPubMedGoogle Scholar
- 36.Miletic AV, Sakata-Sogawa K, Hiroshima M, Hamann MJ, Gomez TS, Ota N, et al. Vav1 acidic region tyrosine 174 is required for the formation of T cell receptor-induced microclusters and is essential in T cell development and activation. J Biol Chem. 2006;281(50):38257–65.CrossRefPubMedPubMedCentralGoogle Scholar